USPTO Registered Patent Agent · Neurobiology · Life Sciences
Advancing our understanding of Alzheimer's disease through hypothesis-driven neuroscience and patent-informed science. My research focuses on the viral etiology of sporadic AD, endosomal trafficking dysfunction, and the molecular biology of APP processing — work that bridges bench science and intellectual property strategy.
Richelle Cutler, PhD — Oskar Fischer Prize Competition
This hypothesis proposes that occult neurotropic alphaherpesvirus infection of adrenergic neurons in the locus coeruleus is the gateway event in herpesvirus-mediated Alzheimer's disease pathogenesis. Multiple herpesvirus types — including HSV-1, HSV-2, VZV, HCMV, HHV-6, and EBV — encode factors that induce endocytic dysfunction by interacting with endosomal proteins and APP processing pathways. The model explains non-cell autonomous neurodegeneration via secreted viral factors, including glycoprotein B, pp150, and EBERs, that produce diffuse degeneration with relatively few infected cells.
Richelle Cutler, PhD — Hypothesis Generation & Critical Analysis
This doctoral thesis presents a comprehensive critical analysis of the herpesvirus AD hypothesis evaluated against the Convergent Autophagic Collapse (CAC) framework — a six-stage model describing progression from lysosomal acidification failure to neuronal lysis and plaque formation. The analysis confirms the hypothesis offers a sophisticated "upstream" explanation for CAC, particularly regarding viral-induced traffic jam via pp150/Rab6/BicD1, C99 accumulation, and molecular mimicry as drivers of PANTHOS formation. Scores 5/5 for Novelty, Relevance, and Clinical Potential.
Thoughts on Alzheimer's research, patent strategy in life sciences, emerging findings in herpesvirus neuroscience, and the intersection of intellectual property and translational medicine.
I am Richelle Gayle Cutler, PhD, a neuroscientist and USPTO Registered Patent Agent (Reg. No. 73581) with over 15 years of experience spanning academic research, intellectual property law, and life science investment analysis.
My doctoral training in Neurobiology at the University of Tennessee Health Science Center Neuroscience Institute and my postdoctoral work at the Johns Hopkins Hospital Wilmer Eye Institute established a deep foundation in cellular neuroscience, transgenic models, and non-cell-autonomous degeneration — themes that continue to shape my Alzheimer's research.
My current research focuses on a herpesviral etiology for sporadic Alzheimer's disease. I propose that neurotropic alphaherpesviruses infecting the locus coeruleus produce widespread neurodegeneration via secreted factors — explaining why so few infected cells can cause so much damage. This model has direct implications for antiviral and adrenergic therapeutic strategies.
As a Life Science Patent Agent at Honigman LLP, I draft and prosecute U.S. and international patent applications in recombinant fusion proteins, antibodies, CRISPR gene editing, RNA interference, and small molecule drugs.
I welcome collaboration with researchers, clinicians, and industry partners working at the intersection of neuroscience, virology, and Alzheimer's therapeutics. I am also available for patent prosecution consultation in life sciences and biotech.
Download Résumé ↗